瑞普生物(300119.SZ)：3個產品獲獸藥產品批准文號
格隆匯1月23日丨瑞普生物(300119.SZ)公佈，公司空港經濟區分公司、全資子公司瑞普(天津)生物藥業有限公司(“瑞普天津”)，近日獲得由農業農村部核發的獸藥產品批准文號。
豬鏈球菌病、副豬嗜血桿菌病二聯亞單位疫苗是將反向疫苗學與蛋白質組技術相結合，應用大數據篩選並分別鑑定出針對豬鏈球菌優勢血清型2型、7型的2種免疫保護性抗原和針對副豬嗜血桿菌優勢血清型4型、5型的2種免疫保護性抗原，應用大腸桿菌工程菌分別表達4種新型蛋白抗原，配合優質佐劑，研製出的世界首個具有完全自主知識產權的可以同時預防豬鏈球菌病、副豬嗜血桿菌病的基因工程亞單位疫苗，科技成果經鑑定達到國際領先水平，屬於國家一類新獸藥。豬鏈球菌病、副豬嗜血桿菌病二聯亞單位疫苗提供對豬鏈球菌2型、7型以及副豬嗜血桿菌15個血清型流行毒株的免疫保護，抗原譜廣、免疫原性優異。本產品抗原成分為純化的有效蛋白，摒棄了細菌培養液中其它無效成分，避免疫苗中微生物大量無效成分對動物機體產生無意義的免疫應答，相比目前市場上其它全菌滅活疫苗或弱毒疫苗，其免疫副作用更小，安全性更高，免疫效果優良。該獸藥生產批准文號的獲得，不僅補充了公司豬用疫苗品種，同時對提高我國豬病防控水平、進而減少抗生素使用量具有重要意義。
異氟烷(寵物用)和吸入用七氟烷(寵物用)二者均屬於吸入性麻醉劑，可用於犬、貓外科手術的麻醉誘導和麻醉維持，操作簡單，易於調控且麻醉效果顯著。吸入麻醉劑溶入細胞膜的脂質層，使脂質分子排列紊亂，膜蛋白質及鈉、鉀通道發生構象和功能上的改變，抑制神經細胞除極，進而廣泛抑制神經衝動的傳遞，導致全身麻醉，通常在3-15分鐘產生麻醉效果，是臨牀上使用最為便捷、安全的麻醉劑類型。其中：異氟烷具有快速誘導和甦醒、低脂溶性、無需肝代謝、對肝腎病動物安全、有良好的肌鬆作用、對心功能影響小等優點，在小動物臨牀上適合各類手術的麻醉維持；吸入用七氟烷則擁有更低的溶解係數、比異氟烷更快的誘導和甦醒、有芳香氣味、易於氣管插管、擁有更大的MAC值(腦血分佈系數)。上述產品上市將繼續豐富公司寵物藥品在寵物醫院臨牀上的應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
